Zhenyu Yang1,2, Chibin Bu1,2, Wei Yuan1,2, Zhaohua Shen1,2, Yongsheng Quan1,2, Shuai Wu1,2, Changxin Zhu1,2, Xiaoyan Wang3,4. 1. Department of Gastroenterology, Third Xiangya Hospital, Central South University, Changsha, Hunan, China. 2. Hunan Key Laboratory of Non-resolving Inflammation and Cancer, Changsha, Hunan, China. 3. Department of Gastroenterology, Third Xiangya Hospital, Central South University, Changsha, Hunan, China. wxy20011@163.com. 4. Hunan Key Laboratory of Non-resolving Inflammation and Cancer, Changsha, Hunan, China. wxy20011@163.com.
Abstract
BACKGROUND AND AIMS: Crohn's disease (CD) is a chronic inflammatory bowel disorder associated with intestinal dysbiosis. This study aimed to determine the efficacy and safety of different methods of fecal microbiota transplantation (FMT), a potential therapy for CD. METHODS:Patients with CD were randomized to receive FMT by gastroscopy or colonoscopy; a second transplantation was performed 1 week later. Patients were assessed by clinical evaluation and serum testing (at weeks 1, 2, 4, 6, and 8) and endoscopy (8 weeks after transplantation). Fecal DNA was extracted and analyzed using the Illuminal sequencing platform. RESULTS: Of the 27 patients included in the study, clinical remission was achieved in 18 (66.7%); no significant difference was seen between the two methods. 76.9% of gastroscopy group patients and 64.3% of colonoscopy group patients experienced mild adverse events during or shortly after treatment. Microbiota diversity analyses showed that, in comparison with the donors, patients had lower operational taxonomic units (OTU; 117 vs. 258, p < 0.05) and Shannon diversity index (2.05 vs. 3.46, p < 0.05). The CD patients showed a significant increase in OTU and Shannon diversity index 2 weeks after FMT. In comparison with the donors, CD patients had lower levels of Bacteroides, Eubacterium, faecalibacterium, and Roseburia, and higher levels of Clostridium, Cronobacter, Fusobacterium, and Streptococcus. CONCLUSIONS:FMT was seen to be safe and effective in this cohort of patients with CD. No significant differences in clinical remission rate and adverse events were seen between the gastroscopy and colonoscopy groups. FMT was seen to increase the species richness in CD patients.
RCT Entities:
BACKGROUND AND AIMS: Crohn's disease (CD) is a chronic inflammatory bowel disorder associated with intestinal dysbiosis. This study aimed to determine the efficacy and safety of different methods of fecal microbiota transplantation (FMT), a potential therapy for CD. METHODS:Patients with CD were randomized to receive FMT by gastroscopy or colonoscopy; a second transplantation was performed 1 week later. Patients were assessed by clinical evaluation and serum testing (at weeks 1, 2, 4, 6, and 8) and endoscopy (8 weeks after transplantation). Fecal DNA was extracted and analyzed using the Illuminal sequencing platform. RESULTS: Of the 27 patients included in the study, clinical remission was achieved in 18 (66.7%); no significant difference was seen between the two methods. 76.9% of gastroscopy group patients and 64.3% of colonoscopy group patients experienced mild adverse events during or shortly after treatment. Microbiota diversity analyses showed that, in comparison with the donors, patients had lower operational taxonomic units (OTU; 117 vs. 258, p < 0.05) and Shannon diversity index (2.05 vs. 3.46, p < 0.05). The CDpatients showed a significant increase in OTU and Shannon diversity index 2 weeks after FMT. In comparison with the donors, CDpatients had lower levels of Bacteroides, Eubacterium, faecalibacterium, and Roseburia, and higher levels of Clostridium, Cronobacter, Fusobacterium, and Streptococcus. CONCLUSIONS: FMT was seen to be safe and effective in this cohort of patients with CD. No significant differences in clinical remission rate and adverse events were seen between the gastroscopy and colonoscopy groups. FMT was seen to increase the species richness in CDpatients.
Authors: Paul Moayyedi; Michael G Surette; Peter T Kim; Josie Libertucci; Melanie Wolfe; Catherine Onischi; David Armstrong; John K Marshall; Zain Kassam; Walter Reinisch; Christine H Lee Journal: Gastroenterology Date: 2015-04-07 Impact factor: 22.682
Authors: Stephan J Ott; Georg H Waetzig; Ateequr Rehman; Jacqueline Moltzau-Anderson; Richa Bharti; Juris A Grasis; Liam Cassidy; Andreas Tholey; Helmut Fickenscher; Dirk Seegert; Philip Rosenstiel; Stefan Schreiber Journal: Gastroenterology Date: 2016-11-17 Impact factor: 22.682
Authors: Ilan Youngster; George H Russell; Christina Pindar; Tomer Ziv-Baran; Jenny Sauk; Elizabeth L Hohmann Journal: JAMA Date: 2014-11-05 Impact factor: 56.272
Authors: J Gregory Caporaso; Justin Kuczynski; Jesse Stombaugh; Kyle Bittinger; Frederic D Bushman; Elizabeth K Costello; Noah Fierer; Antonio Gonzalez Peña; Julia K Goodrich; Jeffrey I Gordon; Gavin A Huttley; Scott T Kelley; Dan Knights; Jeremy E Koenig; Ruth E Ley; Catherine A Lozupone; Daniel McDonald; Brian D Muegge; Meg Pirrung; Jens Reeder; Joel R Sevinsky; Peter J Turnbaugh; William A Walters; Jeremy Widmann; Tanya Yatsunenko; Jesse Zaneveld; Rob Knight Journal: Nat Methods Date: 2010-04-11 Impact factor: 28.547
Authors: J Gregory Caporaso; Christian L Lauber; William A Walters; Donna Berg-Lyons; James Huntley; Noah Fierer; Sarah M Owens; Jason Betley; Louise Fraser; Markus Bauer; Niall Gormley; Jack A Gilbert; Geoff Smith; Rob Knight Journal: ISME J Date: 2012-03-08 Impact factor: 10.302
Authors: Alexa Weingarden; Antonio González; Yoshiki Vázquez-Baeza; Sophie Weiss; Gregory Humphry; Donna Berg-Lyons; Dan Knights; Tatsuya Unno; Aleh Bobr; Johnthomas Kang; Alexander Khoruts; Rob Knight; Michael J Sadowsky Journal: Microbiome Date: 2015-03-30 Impact factor: 14.650
Authors: James R Cole; Qiong Wang; Jordan A Fish; Benli Chai; Donna M McGarrell; Yanni Sun; C Titus Brown; Andrea Porras-Alfaro; Cheryl R Kuske; James M Tiedje Journal: Nucleic Acids Res Date: 2013-11-27 Impact factor: 16.971
Authors: Luciane de Fátima Caldeira; Helena H Borba; Fernanda S Tonin; Astrid Wiens; Fernando Fernandez-Llimos; Roberto Pontarolo Journal: PLoS One Date: 2020-09-18 Impact factor: 3.240
Authors: Valentin Mocanu; Sabitha Rajaruban; Jerry Dang; Janice Y Kung; Edward C Deehan; Karen L Madsen Journal: J Clin Med Date: 2021-03-01 Impact factor: 4.241